Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

Earlens Announces Partnership with Verily

June 13, 2020

Earlens announced they have entered into a strategic agreement with Verily, an Alphabet company, to develop next-generation capabilities for the Earlens® Contact Hearing Solution.

According to the Hearing Loss Association of America, about 20 percent of Americans, or 48 million people, report some degree of hearing loss. Yet, research estimates that only 1 in 5 individuals who might benefit from treatment seek help. A major factor in the underutilization of hearing aids is disappointment with the quality and clarity of sound that conventional hearing devices, like acoustic hearing aids and amplifiers, provide. Earlens has developed a novel way to overcome these sound quality limitations by creating sound without an acoustic signal.

“Unlike traditional hearing aids that amplify sound through a speaker, Earlens uses a small lens to vibrate the eardrum, which directly activates the natural hearing process and delivers the broadest bandwidth available today,” said Bill Facteau, Earlens president and chief executive officer. “By combining our complementary sets of expertise, we aim to develop a next-generation hearing solution, as well as explore modalities for monitoring that may address conditions beyond hearing loss.”

Earlens believes Verily’s capabilities make Verily a natural partner as Earlens expands the capabilities and impact of its solutions. While some acoustic hearing aids have announced new AI capabilities and overall wellness benefits, they are typically only worn for part of the day, while the Lens in the Earlens solution remains in the ear at all times.

“Verily’s extensive experience in custom miniaturized, low-power and integrated medical devices uniquely position us to enhance the Earlens solution with a smaller, more efficient and more powerful behind-the-ear device,” said Brian Otis, chief technical officer, Verily. “Earlens is the only hearing solution that places a lens on the eardrum, and by combining our innovative medical, wearable and sensor technologies, we can further revolutionize the industry to support patients dealing with hearing challenges.”

SourceEarlens
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy